The diverse role of miR-31 in regulating cancer associated phenotypes

Genes Chromosomes and Cancer

Volumn 52, Issue 12, 2013, Pages 1103-1113

  Laurila, Eeva M ^a   Kallioniemi, Anne ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b FIMLAB LABORATORIES   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; FLUOROURACIL; INTEGRIN; LONG UNTRANSLATED RNA; MICRORNA 31; PACLITAXEL;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER GENETICS; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER THERAPY; CELL FUNCTION; CELL LOSS; CELL MIGRATION; CELL PROLIFERATION; CELL TYPE; CELL VIABILITY; CHROMOSOME BAND; COLON CANCER; COLORECTAL CANCER; COMPARATIVE STUDY; DNA REPLICATION; ENDOMETRIUM CANCER; ENDOTHELIUM CELL; ESOPHAGUS CANCER; FIBROBLAST; GENE CONTROL; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; GLIOMA; GLYCOGEN METABOLISM; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTONE METHYLATION; HUMAN; LEUKEMIA; LUNG CANCER; MELANOMA; MESOTHELIOMA; MOUTH CANCER; MULTIMODALITY CANCER THERAPY; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RNA METHYLATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASMS; PHENOTYPE;

EID: 84886232938     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22107     Document Type: Article

References (70)

1. Aprelikova O, Yu X, Palla J, Wei BR, John S, Yi M, Stephens R, Simpson RM, Risinger JI, Jazaeri A, Niederhuber J. 2010. The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. Cell Cycle 9:4387-4398.
2. Asangani IA, Harms PW, Dodson L, Pandhi M, Kunju LP, Maher CA, Fullen DR, Johnson TM, Giordano TJ, Palanisamy N, Chinnaiyan AM. 2012. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget 3:1011-1025.
3. Augoff K, Das M, Bialkowska K, McCue B, Plow EF, Sossey-Alaoui K. 2011. miR-31 is a broad regulator of beta1-integrin expression and function in cancer cells. Mol Cancer Res 9:1500-1508.
4. Augoff K, McCue B, Plow EF, Sossey-Alaoui K. 2012. miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. Mol Cancer 11:5.
5. Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzo M, Garcia-Foncillas J. 2006. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 5:29.
6. Bartel DP. 2009. MicroRNAs: Target recognition and regulatory functions. Cell 136:215-233.
7. Bhatnagar N, Li X, Padi SK, Zhang Q, Tang MS, Guo B. 2010. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 1:e105.
8. Cekaite L, Rantala JK, Bruun J, Guriby M, Agesen TH, Danielsen SA, Lind GE, Nesbakken A, Kallioniemi O, Lothe RA, Skotheim RI. 2012. MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia 14:868-879.
9. Chan YT, Lin YC, Lin RJ, Kuo HH, Thang WC, Chiu KP, Yu AL. 2013. Concordant and discordant regulation of target genes by miR-31 and its isoforms. PLoS One 8:e5819.
10. Chang KW, Kao SY, Wu YH, Tsai MM, Tu HF, Liu CJ, Lui MT, Lin SC. 2013. Passenger strand miRNA miR-31* regulates the phenotypes of oral cancer cells by targeting RhoA. Oral Oncol 49:27-33.
11. Cottonham CL, Kaneko S, Xu L. 2010. miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem 285:35293-35302.
12. Creighton CJ, Fountain MD, Yu Z, Nagaraja AK, Zhu H, Khan M, Olokpa E, Zariff A, Gunaratne PH, Matzuk MM, Anderson ML. 2010. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res 70:1906-1915.
13. Dai N, Zhong ZY, Cun YP, Qing Y, Chen C, Jiang P, Li MX, Wang D. 2013. Alteration of the microRNA expression profile in human osteosarcoma cells transfected with APE1 siRNA. Neoplasma 60:384-394.
14. Friedman RC, Farh KK, Burge CB, Bartel DP. 2009. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19:92-105.
15. Fuse M, Kojima S, Enokida H, Chiyomaru T, Yoshino H, Nohata N, Kinoshita T, Sakamoto S, Naya Y, Nakagawa M, Ichikawa T, Seki N. 2012. Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. J Hum Genet 57:691-699.
16. Greenberg E, Hershkovitz L, Itzhaki O, Hajdu S, Nemlich Y, Ortenberg R, Gefen N, Edry L, Modai S, Keisari Y, Besser MJ, Schachter J, Shomron N, Markel G. 2011. Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One 6:e18936.
17. Gunaratne PH, Creighton CJ, Watson M, Tennakoon JB. 2010. Large-scale integration of MicroRNA and gene expression data for identification of enriched microRNA-mRNA associations in biological systems. Methods Mol Biol 667:297-315.
18. Hammond SM. 2006. MicroRNAs as oncogenes. Curr Opin Genet Dev 16:4-9.
19. He L, Hannon GJ. 2004. MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet 5:522-531.
20. Hua D, Ding D, Han X, Zhang W, Zhao N, Foltz G, Lan Q, Huang Q, Lin B. 2012. Human miR-31 targets radixin and inhibits migration and invasion of glioma cells. Oncol Rep 27:700-706.
21. Iorio MV, Croce CM. 2012. MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4:143-159.
22. Ivanov SV, Goparaju CM, Lopez P, Zavadil J, Toren-Haritan G, Rosenwald S, Hoshen M, Chajut A, Cohen D, Pass HI. 2010. Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem 285:22809-22817.
23. Krol J, Loedige I, Filipowicz W. 2010. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11:597-610.
24. Laurila EM, Sandstrom S, Rantanen LM, Autio R, Kallioniemi A. 2012. Both inhibition and enhanced expression of miR-31 lead to reduced migration and invasion of pancreatic cancer cells. Genes Chromosomes Cancer 51:557-568.
25. Li Y, Pei J, Xia H, Ke H, Wang H, Tao W. 2003. Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene 22:4398-4405.
26. Lin PC, Chiu YL, Banerjee S, Park K, Mosquera JM, Giannopoulou E, Alves P, Tewari AK, Gerstein MB, Beltran H, Melnick AM, Elemento O, Demichelis F, Rubin MA. 2013. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res 73:1232-1244.
27. Liu CJ, Kao SY, Tu HF, Tsai MM, Chang KW, Lin SC. 2010a. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis 16:360-364.
28. Liu CJ, Tsai MM, Hung PS, Kao SY, Liu TY, Wu KJ, Chiou SH, Lin SC, Chang KW. 2010b. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res 70:1635-1644.
29. Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, Demidenko E, Korc M, Shi W, Preis M, Dragnev KH, Li H, Direnzo J, Bak M, Freemantle SJ, Kauppinen S, Dmitrovsky E. 2010c. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 120:1298-1309.
30. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. 2005. MicroRNA expression profiles classify human cancers. Nature 435:834-838.
31. Lu Z, Ye Y, Jiao D, Qiao J, Cui S, Liu Z. 2012. miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. Oncol Lett 4:1027-1032.
32. Lynam-Lennon N, Reynolds JV, Marignol L, Sheils OM, Pidgeon GP, Maher SG. 2012. MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. J Mol Med (Berl) 90:1449-1458.
33. McClatchey AI. 2003. Merlin and ERM proteins: Unappreciated roles in cancer development? Nat Rev Cancer 3:877-883.
34. miRBase release 19, Available at: http://www.mirbase.org/. 2012.
35. Mitamura T, Watari H, Wang L, Kanno H, Hassan MK, Miyazaki M, Katoh Y, Kimura T, Tanino M, Nishihara H, Tanaka S, Sakuragi N. 2013. Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis 2:e40.
36. Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, Lengyel E. 2012. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov 2:1100-1108.
37. Mosakhani N, Lahti L, Borze I, Karjalainen-Lindsberg ML, Sundstrom J, Ristamaki R, Osterlund P, Knuutila S, Sarhadi VK. 2012. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF. Cancer Genet 205:545-551.
38. Namlos HM, Meza-Zepeda LA, Baroy T, Ostensen IH, Kresse SH, Kuijjer ML, Serra M, Burger H, Cleton-Jansen AM, Myklebost O. 2012. Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One 7:e48086.
39. Peng H, Hamanaka RB, Katsnelson J, Hao LL, Yang W, Chandel NS, Lavker RM. 2012a. MicroRNA-31 targets FIH-1 to positively regulate corneal epithelial glycogen metabolism. FASEB J 26:3140-3147.
40. Peng H, Kaplan N, Hamanaka RB, Katsnelson J, Blatt H, Yang W, Hao L, Bryar PJ, Johnson RS, Getsios S, Chandel NS, Lavker RM. 2012b. microRNA-31/factor-inhibiting hypoxia-inducible factor 1 nexus regulates keratinocyte differentiation. Proc Natl Acad Sci USA 109:14030-14034.
41. Pritchard CC, Cheng HH, Tewari M. 2012. MicroRNA profiling: Approaches and considerations. Nat Rev Genet 13:358-369.
42. Schee K, Boye K, Abrahamsen TW, Fodstad O, Flatmark K. 2012. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer 12:505-2407-12-505.
43. Schmittgen TD. 2010. miR-31: a master regulator of metastasis? Future Oncol 6:17-20.
44. Sherr CJ. 2001. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2:731-737.
45. Sherr CJ. 2012. Ink4-Arf Locus in Cancer and Aging. Wiley Interdiscip Rev Dev Biol 1:731-741.
46. Shtrichman R, Sharf R, Barr H, Dobner T, Kleinberger T. 1999. Induction of apoptosis by adenovirus E4orf4 protein is specific to transformed cells and requires an interaction with protein phosphatase 2A. Proc Natl Acad Sci USA 96:10080-10085.
47. Siow M, Karen Ng L, Vincent Chong V, Jamaludin M, Abraham M, Abdul Rahman Z, Kallarakkal T, Yang YH, Cheong S, Zain R. 2013. Dysregulation of miR-31 and miR-375 expression is associated with clinical outcomes in oral carcinoma. Oral Dis [Epub ahead of print].
48. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R, Vyzula R. 2007. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 72:397-402.
49. Sossey-Alaoui K, Downs-Kelly E, Das M, Izem L, Tubbs R, Plow EF. 2010. WAVE3, an actin remodeling protein, is regulated by the metastasis suppressor microRNA, miR-31, during the invasion-metastasis cascade. Int J Cancer 129:1331-1343.
50. Struckhoff AP, Rana MK, Worthylake RA. 2011. RhoA can lead the way in tumor cell invasion and metastasis. Front Biosci 16:1915-1926.
51. Sun D, Yu F, Ma Y, Zhao R, Chen X, Zhu J, Zhang CY, Chen J, Zhang J. 2013. MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). J Biol Chem 288:9508-9518.
52. Usvasalo A, Ninomiya S, Raty R, Hollmen J, Saarinen-Pihkala UM, Elonen E, Knuutila S. 2010. Focal 9p instability in hematologic neoplasias revealed by comparative genomic hybridization and single-nucleotide polymorphism microarray analyses. Genes Chromosomes Cancer 49:309-318.
53. Valastyan S, Weinberg RA. 2010. miR-31: A crucial overseer of tumor metastasis and other emerging roles. Cell Cycle 9:2124-2129.
54. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC, Brock JE, Richardson AL, Weinberg RA. 2009a. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137:1032-1046.
55. Valastyan S, Benaich N, Chang A, Reinhardt F, Weinberg RA. 2009b. Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis. Genes Dev 23:2592-2597.
56. Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA. 2010. Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res 70:5147-5154.
57. Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA. 2011. Activation of miR-31 function in already-established metastases elicits metastatic regression. Genes Dev 25:646-659.
58. Veerla S, Lindgren D, Kvist A, Frigyesi A, Staaf J, Persson H, Liedberg F, Chebil G, Gudjonsson S, Borg A, Mansson W, Rovira C, Hoglund M. 2009. MiRNA expression in urothelial carcinomas: Important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer 124:2236-2242.
59. Wang CJ, Zhou ZG, Wang L, Yang L, Zhou B, Gu J, Chen HY, Sun XF. 2009. Clinicopathological significance of microRNA-31, -143 and -145 expression in colorectal cancer. Dis Markers 26:27-34.
60. Wang CJ, Stratmann J, Zhou ZG, Sun XF. 2010. Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells. BMC Cancer 10:616.
61. Wang S, Li Q, Wang K, Dai Y, Yang J, Xue S, Han F, Zhang Q, Liu J, Wu W. 2013. Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer. Clin Transl Oncol [Epub ahead of print].
62. Wszolek MF, Rieger-Christ KM, Kenney PA, Gould JJ, Silva Neto B, Lavoie AK, Logvinenko T, Libertino JA, Summerhayes IC. 2009. A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol 29:794-801.
63. Wu YH, Hu TF, Chen YC, Tsai YN, Tsai YH, Cheng CC, Wang HW. 2011. The manipulation of miRNA-gene regulatory networks by KSHV induces endothelial cell motility. Blood 118:2896-2905.
64. Xi S, Yang M, Tao Y, Xu H, Shan J, Inchauste S, Zhang M, Mercedes L, Hong JA, Rao M, Schrump DS. 2010. Cigarette smoke induces C/EBP-beta-mediated activation of miR-31 in normal human respiratory epithelia and lung cancer cells. PLoS One 5:e13764.
65. Xu RS, Wu XD, Zhang SQ, Li CF, Yang L, Li DD, Zhang BG, Zhang Y, Jin JP, Zhang B. 2013. The tumor suppressor gene RhoBTB1 is a novel target of miR-31 in human colon cancer. Int J Oncol 42:676-682.
66. Yamagishi M, Nakano K, Miyake A, Yamochi T, Kagami Y, Tsutsumi A, Matsuda Y, Sato-Otsubo A, Muto S, Utsunomiya A, Yamaguchi K, Uchimaru K, Ogawa S, Watanabe T. 2012. Polycomb-mediated loss of miR-31 activates NIK-dependent NF-kappaB pathway in adult T cell leukemia and other cancers. Cancer Cell 21:121-135.
67. Yang WW, Wang ZH, Zhu Y, Yang HT. 2007. E2F6 negatively regulates ultraviolet-induced apoptosis via modulation of BRCA1. Cell Death Differ 14:807-817.
68. Yang WW, Shu B, Zhu Y, Yang HT. 2008. E2F6 inhibits cobalt chloride-mimetic hypoxia-induced apoptosis through E2F1. Mol Biol Cell 19:3691-3700.
69. Zhong Z, Dong Z, Yang L, Chen X, Gong Z. 2013. MicroRNA-31-5p modulates cell cycle by targeting human mutL homolog 1 in human cancer cells. Tumour Biol 34:1959-1965.
70. Zimmerman AL, Wu S. 2011. MicroRNAs, cancer and cancer stem cells. Cancer Lett 300:10-19.